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Acute graft- vs. -host disease (GVHD) is an important cause of morbidity and death
after allogeneic hematopoietic cell transplantation (HCT). We identify a new approach
to prevent GVHD that impairs monocyte-derived dendritic cell (moDC) alloactivation of
T cells, yet preserves graft- vs.-leukemia (GVL). Exceeding endoplasmic reticulum (ER)
capacity results in a spliced form of X-box binding protein-1 (XBP-1s). XBP-1s mediates
ER stress and inflammatory responses. We demonstrate that siRNA targeting XBP-1
in moDCs abrogates their stimulation of allogeneic T cells. B-I09, an inositol-requiring
enzyme-1α (IRE1α) inhibitor that prevents XBP-1 splicing, reduces human moDC
migration, allo-stimulatory potency, and curtails moDC IL-1β, TGFβ, and p40 cytokines,
suppressing Th1 and Th17 cell priming. B-I09-treated moDCs reduce responder T cell
activation via calcium flux without interfering with regulatory T cell (Treg) function or GVL
effects by cytotoxic T lymphocytes (CTL) and NK cells. In a human T cell mediated
xenogeneic GVHD model, B-I09 inhibition of XBP-1s reduced target-organ damage and
pathogenic Th1 and Th17 cells without impacting donor Tregs or anti-tumor CTL. DC
XBP-1s inhibition provides an innovative strategy to prevent GVHD and retain GVL.
Keywords: GvHD, GvL, er stress, XBP-1S, dendritic cell (DC)
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INTRODUCTION
DCs are a relevant biologic target for GVHD prevention
(1), though current immune suppressive GVHD treatment
strategies primarily act upon donor T cells (2–4). Beyond antigen
presentation and costimulation, DCs produce proinflammatory
cytokines that fuel alloreactive T cells (5). Activated DCs
secrete IL-1β via the inflammasome (6), which promotes the
differentiation of pathogenic Th17 cells (7, 8). In response to ER
stress, the inflammasome is regulated by XBP-1, a transcription
factor that is spliced and activated by the RNAse subunit of IRE1α
(9, 10). XBP-1s allows the ER to synthesize lipids, expand its
size, and produce chaperones to fold ER client proteins that can
protect stressed cells from death (9, 11, 12). Prolonged ER stress
leads to hyperactivation of IRE1α and secondary inflammasome
activation via interactions between XBP-1s and NLRP3 (9, 13).
Additionally, XBP-1s regulates DC responses to inflammatory
stimuli, such as lipopolysaccharide (LPS) (14).
Inflammasome activity within recipient tissue directly impacts
murine GVHD severity (15). NLRP3-deficient mice are partially
protected from acute GVHD, while transfer of allogeneic NLRP3-
deficient donor T cells to normal hosts has no protective effect
(15). This suggests that inflammasome activity in antigen present
cells, and/or DCs, contribute to acute GVHD. Furthermore,
microRNA-155 is known to regulate DC inflammasome activity
(15). MicroRNA-155 deficient murine DCs exhibit impaired IL-
1β production from the inflammasome, and such recipient mice
also develop significantly less severe acute GVHD (16). In other
studies, GVHD but not no GVHD transplant control mice were
shown to induce inflammasome activation in myeloid-derived
suppressor cells within the first 5 days post-transplant resulting in
a loss of their suppressor function (17). Inflammasome activation
has been linked to the expression of the purinergic receptors
P2x7R and P2Y2, that can sense ATP from damage-associated
molecular patterns produced during GVHD, while neutralizing
ATP or purinergic receptor triggering reduces GVHD (18, 19).
Similarly in patients, high ATP levels have been documented
in the peritoneal fluid of patients with severe GVHD (18).
Altogether, this evidence strongly supports the pathogenic role
of the inflammasome in acute GVHD biology (20).
However, translating this concept to clinical transplantation
remains a challenge. Administering IL-1 receptor antagonist
failed to prevent acute GVHD in some (21), but not all (22)
murine models, and in patients treated in the early post- or
peri-HCT period, respectively (23). While the inflammasome
and IL-1β are biologically relevant to GVHD pathogenesis, the
best strategy to target IL-1β and control donor T cells remains
uncertain (15, 23).
Given the fundamental contributions of the inflammasome
to acute GVHD and XBP-1s as a regulator of inflammasome
activation, targeting ER stress via XBP-1s inactivation could
represent a novel strategy to prevent acute GVHD. In support of
this possibility is work in autoimmune syndromes showing that
Abbreviations: GVHD, graft-vs.-host disease; HCT, hematopoietic cell
transplantation; moDC, monocyte-derived dendritic cell; ER, endoplasmic
reticulum; CTL, stress, cytotoxic T lymphocytes ; LPS, lipopolysaccharide; GVL,
graft- vs.-leukemia.
blocking ER stress with tauroursodeoxycholic acid ameliorates
experimental autoimmune encephalomyelitis and reduces Th17
differentiation (24). In a donor B cell dependent chronic GVHD
model, suppressing XBP-1s in donor B cells reduces murine
chronic GVHD (25). While these findings in murine chronic
GVHD are important, translational questions regarding how the
ER stress response influences human acute GVHD pathogenesis
were not addressed.
Our present work is distinct from observations in murine
chronic GVHD, as we demonstrate that siRNA knock down
or a small molecule inhibitor of XBP-1s can ameliorate DC-
allostimulation of human T cells, and using a human skin
xenograft model we show that pharmacologic inhibition of XBP-
1s can reduce donor alloreactivity in vivo. Mechanistically, we
also demonstrate how blocking the ER stress response of DCs
impacts responding donor T cell activation and differentiation.
Herein, we provide human data that support XBP-1s+ DCs are
relevant biologic targets to prevent acute GVHD, without loss of
Treg function or anti-tumor activity by CTLs and NK cells.
MATERIALS AND METHODS
Medium
Unless otherwise stated, cells were cultured in complete RPMI
supplemented with 10% heat-inactivated, pooled human serum
(26).
mAbs and Flow Cytometry
Fluorochrome-conjugated anti-mouse or -human monoclonal
antibodies included anti-CD3, CD4, CD8, CD25, CD25RO,
CD83, CD86, HLA-DR, CD127, CCR6, CCR7, Ki-67, Foxp3,
IFNγ, IL-4, IL-17A, XBP-1s, and phosphorylated STAT3 Y705
(Supplemental Table 1). Live/Dead Fixable Yellow Dead Cell
Stain (Life Technologies) was used to determine viability. Live
events were acquired on a FACSCanto (FlowJo software, ver.
7.6.4).
moDC Phenotyping
LPS-mature moDCs were surfaced stained for CD83, followed
by fixation, permeabilization (eBioscience) and intracellular
staining for XBP-1s. All other moDC maturation phenotyping
was performed as described (19, 21).
siRNA Knock Down of XBP-1
Immature, human moDCs were loaded with XBP-1 or control
siRNAs (Dharmacon) using polyethyleneimine (Polyplus), and
then stimulated with LPS (1µg/ml) for 24 h in the presence of B-
I09 (20µM) or DMSO (0.1%). XBP-1 knock downwas confirmed
by flow cytometry. The moDCs were then used as stimulators in
5-day alloMLRs.
moDC Experiments and alloMLRs
Immature human moDCs were cytokine-generated and
differentiated with LPS as described (27). B-I09, XBP-1s
inhibitor, was synthesized and purified as reported (28). For
XBP-1s expression experiments, moDCs were stimulated with
LPS for 24 h while treated with B-I09 (20µM) or DMSO (0.1%).
Supernatant cytokines were quantified using commercial ELISA
kits (Thermo Fisher Scientific Inc) after 24 h of LPS-stimulation
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in the presence of B-I09 or DMSO. RT-PCR to analyze the levels
of regulated IRE1-dependent decay (RIDD) substrates, and total
and spliced XBP-1 mRNA was performed after LPS stimulation.
moDC chemotaxis was quantified by migration through a
5µm pore filter in the chamber of a 24-well transwell plate (29).
The lower chamber was filled with 500 µl RPMI enriched with
10% heat-inactivated, human pooled serum and B-I09 (20µM)
or DMSO (0.1%). moDCs pre-treated with B-I09 or DMSO
during LPS-maturation were added to the upper chamber at 1
× 105/50 µl. CCL19 or CCL21 (300 ng/ml, R&D systems) was
added to the lower well and moDC migration was analyzed after
3 h.
moDC stimulatory capacity was measured in 5-day allogeneic
mixed leukocyte reactions (alloMLR). Purified T cells were
obtained from healthy human donors (OneBlood) as described
(26). AlloMLRs were plated at a moDC:T cell ratio of 1:30.
The MLRs consisted of DMSO (0.1%) or B-I09 (20µM) pre-
treated moDCs, DMSO or B-I09 treated MLR medium only, or
both. T cell proliferation was determined by a colorimetric assay
(Promega) (26, 30).
Calcium Flux Assay
Human moDCs were stimulated with LPS (1µg/ml) for 24 h
in the presence of B-I09 (20µM) or DMSO (0.1%), and then
used to stimulate allogeneic T cells in 5-day alloMLRs. The T
cells were then rested for 24 h at 37◦C after primary stimulation,
transferred to FluoroDish (WPI, 35mm, 5 × 105 T cells/200 µl)
plates coated with Cell-Tak (Corning), loaded with Fluo-4 dye
(Thermofisher) for 30min and washed, and finally restimulated
with fresh B-I09- or DMSO-treated moDCs (3× 104) during live
cell imaging to monitor calcium flux in real time (Moffitt Cancer
Center, Analytic Microscopy Core).
Live T cells were observed with a Leica TCS SP8 AOBS
laser scanning confocal microscope through a 20X/0.8NA or
40X/1.3NA Plan Apochromat objective lens (Leica Microsystems
CMS GmbH, Germany). A 488 nm laser line was applied to
excite the sample and tunable emission was set to capture the
Fluo-4 spectrum. Images were captured at 400Hz scan speed
with photomultiplier detectors and LAS X software version 3.1.5
(Leica Microsystems).
Time lapse images were analyzed using the Definiens Tissue
Studio v4.7 (Definiens AG, Munich, Germany) software suite.
The green fluorescent channel images were segmented by green
intensity and cell size. The image was analyzed as an 8 bit image
and intensity was measured from 0 to 255 grayscale fluorescent
units. The cells were then quantified for green intensity per field
for each time point imaged and then plotted for intensity over
time.
REVERSE TRANSCRIPTION AND
QUANTITATIVE POLYMERASE CHAIN
REACTION (qPCR) TO DETECT THE
EXPRESSION LEVELS OF RIDD
SUBSTRATES
Human moDCs were stimulated with LPS (1µg/ml) for 24 h
in the presence of B-I09 (20µM) or DMSO (0.1%). moDCs
were then harvested and total RNA was isolated using TRIzol
reagent (Invitrogen). Complementary DNA was synthesized
fromRNAusingMaximaHMinus reverse transcriptase (Thermo
Scientific). The following sets of primers were used together with
iTaq Universal SYBR Green Supermix (Roche) in qPCR to detect
the expression levels of human GAPDH (GGA TGA TGT TCT
GGAGAGCC and CATCACCATCTTCCAGGAGC); human
XBP1s (CTG AGT CCG AAT CAG GTG CAG and ATC CAT
GGG GAG ATG TTC TGG); human XBP1t (TGG CCG GGT
CTG CTG AGT CCG and ATC CAT GGG GAG ATG TTC
TGG); human Bloc1S1 (CCCAATTTGCCAAGCAGACA and
CAT CCC CAA TTT CCT TGA GTG C); human CD59 (TGA
TGC GTG TCT CAT TAC CAA AGC and ACA CAG GTC CTT
CTT GCA GCA G); and human Scara3 (AAC TTC CTG CAC
ACA CTG GC and CAA ACC AGT TGC ACA TCC AG).
Treg Experiments
Tregs were defined as CD4+, CD127−, CD25+, Foxp3+ cells
(31, 32). Treg potency was determined using suppression assays
(26). DMSO (0.1%) or B-I09 (20µM) was only added to the
initial culture to expand the Tregs. No drug was added to the
suppression assay medium. Conventional, alloreactive T cell
(Tconv) proliferation was measured by Ki-67 expression using
flow cytometry. To test the effect of XBP-1s blockade on natural
(nTreg) or in vitro induced Tregs (iTreg), circulating Tregs were
isolated from healthy donor blood by magnetic bead purification
(CD4+, CD25+). Tconv (CD4+, CD25−) were also purified from
the donor sample and stimulated with allogeneic moDCs and
IL-2 for iTreg differentiation. The enriched nTregs were also
cultured with IL-2 (20IU/ml) and allogeneic moDCs (pretreated
with DMSO or B-I09) at a ratio of 1:30. DMSO (0.1%) or B-
I09 (20µM) was added to the co-culture once on day 0 as
indicated. After 5 days, the cells were harvested and analyzed
by flow cytometry. Tregs were enumerated using CountBright
beads (Thermo Fisher Scientific Inc). In select experiments,
TGFβ1 (4 ng/ml) (R&D Systems) was added to the medium on
alternating days.
Th1, Th2, and Th17 Phenotype Experiments
T cells were cultured with DMSO- or B-I09-pretreated, allogeneic
moDCs, DMSO (0.1%) or B-I09 (20µM) was added once on
day 0. For Th17 experiments only, the T cells were first CD4-
purified bymagnetic bead isolation and supplemented with IL-1β
or TGFβ as indicated, and anti-IFNγ antibody (26). On day +5,
the T cells were harvested and stained to identify the following T
helper subsets: Th17 - CD4+, IL-17A+; Th1 - CD4+, IFNγ+; and
Th2 - CD4+, IL-4+.
Tumor Lysis Experiments and T Cell Recall
Response
Human peripheral blood mononuclear cells (PBMCs, 5x105)
were stimulated with irradiated (30Gy) U937 cells (American
Type Culture Collection) at a 1:1 ratio on day 0 and +7. DMSO
(0.1%) or B-I09 (20µM) was added on day 0. CD8+ T cells
were isolated on days +12-14 (to prevent non-specific killing
by NK cells), and then cultured with fresh U937 cells at the
stated effector-to-target ratios for 4 h at 37◦C (26). Unprimed
CD8+ T cells served as a negative control. No drug was added.
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Tumor lysis was determined by a colorimetric LDH release
assay (Thermo Fisher Scientific Inc) (26, 33). Percent lysis was
calculated as follows: [(test optical density (OD) – spontaneous
OD)/(maximum OD – spontaneous OD)]× 100 (26, 33).
To determine T cell recall response to nominal antigen, T
cells were cultured with autologous moDCs loaded with a mixed
CMV, EBV, influenza, and tetanus peptide pool (JPT). DMSO
(0.1%) or B-I09 (20µM) was added once on day 0 of the culture.
T cell proliferation was determined after 3 days of culture (34).
NK Cell Experiments
Human natural killer cells (NK cells) were isolated from healthy
donor PBMCs by magnetic bead purification (Miltenyi Biotec
Inc). NK cells were cultured with K562 cells at the stated
effector-to-target ratios for 5 h at 37◦C in the presence of DMSO
(0.1%) or B-I09 (20µM) (35). Tumor lysis was determined by a
colorimetric LDH release assay (33, 35).
NK cell proliferation was assessed by allogeneic moDC
(moDC: NK cell ratio 1:10) or cytokine stimulation (IL-2 200
IU/ml and IL-15 10 ng/ml) (35). DMSO (0.1%) or B-I09 (20µM)
was added once on day 0 of the culture. NK cell proliferation was
determined after 5 days using a colorimetric assay.
Xenograft Model and in vivo CTL
Generation
NSGmice were transplanted with a 1 cm2 human skin graft using
a well-established model (33, 36, 37). Skin was procured from
consented mastectomy patients (MCC 17634, an IRB-approved
protocol). After 30 days of rest, mice received 5 × 106 fresh,
human PBMCs (OneBlood) i.p. using a random donor allogeneic
to the skin graft (26, 36, 37). Each transplant experiment used
a unique donor pair of skin and PBMCs. B-I09 30 mg/kg
or a polyethylene glycol-based vehicle (26) was given by i.p.
injection 5 days a week for 3 weeks. On day +21, mice were
humanely euthanized; skin grafts, host lung, host liver, and host
spleen were harvested for analysis. Skin rejection and xenogeneic
GVHD scoring was performed blinded according to standard
criteria (26, 33, 38). Processed spleens cells were phenotyped
by flow cytometry. To generate CD8+ CTL in vivo, mice were
transplanted with 30 × 106 human PBMCs and also received
irradiated U937 cells (10x106) on day 0 and +7 (26, 33). Control
mice received PBMCs alone without tumor. Mice did not receive
skin grafts for these experiments. Mice received B-I09 or vehicle
exactly as stated. On days +10-12, the mice were humanely
euthanized and the spleens were harvested. Human CD8+ T cells
within the spleens were purified by magnetic beads. Tumor lysis
assays were performed in vitro.
NSG Mice for Xenograft Model and in vivo
CTL Generation
NSG mice (male or female, 6–24 weeks old) were used in
the described in vivo experiments. NSG mice were purchased
from The Jackson Laboratory and raised at the Moffitt Cancer
Center vivarium. Experiments were performed according to
an Institutional Animal Care and Use Committee (IACUC)–
approved protocol in adherence to the National Institutes of
Health’s Guide for the Care and Use of Laboratory Animals.
Statistical Analysis
Data are reported as mean values±SEM. Normality was tested by
the Anderson-Darling test. For comparisons of dependent data,
the paired t-test was used. The Mann-Whitney test was used
for comparisons of in vivo mouse and patient skin sample data.
ANOVA was used for group comparisons, including a Dunnett’s
or Tukey post-test with correction formultiple-comparisons. The
statistical analysis was conducted using Prism software version
5.04 (GraphPad). Statistical significance was defined by P < 0.05
(two-tailed).
RESULTS
XBP-1s Inhibition Reduces the Stimulatory
Potency of moDCs Toward Allogeneic T
Cells
XBP-1 mRNA is constitutively spliced by IRE1α in moDCs
at steady-state (14, 39). The TLR4 agonist, LPS, triggers ER
stress and augments XBP-1 splicing (40). We first tested the
effect of XBP-1s blockade on human moDC stimulatory capacity
in alloMLRs. To genetically suppress XBP-1s, human moDCs
were treated with XBP-1 or control siRNA and stimulated with
LPS for 24 h (Figure 1A). Allogeneic T cells responding to the
XBP-1 siRNA-treated moDCs showed a significant reduction in
proliferation compared to controls (Figure 1B).
B-I09 blocks the RNAse activity of IRE1α, suppressing XBP-
1 splicing (28). B-I09 (20µM) has shown on-target XBP-
1s inhibition in murine B cells and chronic lymphocytic
leukemia (28). Similar to its effects on murine B cells, B-
I09 significantly reduces XBP-1s in human, LPS-stimulated
moDCs (Supplemental Figures 1A,B). We confirmed on-target
inhibition of XBP-1s in moDCs by B-I09 via RNA expression,
and verified that key regulated IRE1 dependent decay (RIDD)
substrates, BlocS1 (41) and CD59 (42), were unaffected by the
inhibitor compared to DMSO (Figure 1C). IRE1α also exhibits
kinase activity and phosphorylates c-Jun N-terminal kinase
(JNK) in response to ER stress (43). Disruption of JNK signaling
could interfere with moDC function (44). However, B-I09 did
not suppress IRE1α-mediated JNK phosphorylation in human
moDCs (Supplemental Figures 2A,B).
Despite the inhibitory effect of B-I09 on moDC XBP-1
splicing, B-I09 did not impair LPS-mediated moDC maturation
or viability (Supplemental Figures 3A–D). Pre-treating the
moDCs with B-I09 (20µM) during LPS-maturation had no
significant effect on the stimulation of allogeneic T cell
proliferation (Figure 1D, condition 1 vs. condition 4). Adding
B-I09 to the allogeneic co-culture alone produced a modest
reduction in T cell proliferation (Figure 1D, condition 2 vs.
condition 5). moDC-allostimulated T cell proliferation was
significantly impaired when the moDCs were first pre-treated
with B-I09 during LPS-maturation and added once again to
the alloMLR medium (Figure 1D, condition 3 vs. condition
6). Therefore, moDCs require XBP-1s suppression during
maturation and also during their interactions with T cells to
fully inhibit the alloresponse. Based on these data, allogeneic
co-cultures described hereafter used either DMSO- (0.1%) or
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FIGURE 1 | XBP-1s inhibition reduces the stimulatory potency of moDCs toward allogeneic T cells. Human moDCs were stimulated with LPS (1µg/ml) for 24 h in the
presence of XBP-1 or control siRNA. (A) Representative histograms show XBP-1s expression in siRNA-treated moDCs. (B) T cells were stimulated by XBP-1- or
control-siRNA-treated moDCs in alloMLRs. T cell proliferation (MTS colormetric assay) after 5 days is shown. AlloMLRs were plated in replicates of 5 at a moDC: T cell
ratio of 1:30. 1 representative experiment of 2 independent studies is shown, Dunnett’s test. (C) Human moDCs were stimulated with LPS (1µg/ml) for 24 h in the
presence of B-I09 (20µM) or DMSO (0.1%). Bar graph shows triplicate mean XBP-1s or total XBP-1 mRNA, vs. the RIDD components BlocS1 and CD59 in B-I09- or
DMSO-treated moDCs after 24 h of LPS stimulation as measured by RT-PCR. 1 representative experiment of 4 independent studies is shown, Tukey’s test. (D) T cell
proliferation (MTS colormetric assay) measured in 5-day MLRs using B-I09- or DMSO-treated allogeneic, moDCs. Table depicts whether moDCs were pre-treated
with DMSO (0.1%) or B-I09 (20µM), or if DMSO (0.1%) or B-I09 (20µM) was added to the MLR medium. Replicate means from 4 independent experiments are
shown, Dunnett’s test. (E,F) Human moDCs were LPS-stimulated for 24 h with B-I09 or DMSO. Bar graphs show proportion of migrating moDCs in transwell assays
testing CCL19 or CCL21 (300 ng/ml, 3 h) chemotaxis. Replicate means from 4 independent experiments are shown for each, Dunnett’s test. (G) Human moDCs were
stimulated with LPS (1µg/ml) for 24 h in the presence of B-I09 (20µM) or DMSO (0.1%), and then used to activate allogeneic T cells for 5 days. T cells were rested for
24 h at 37◦C, loaded with Fluo-4 dye for 30min, then restimulated with fresh B-I09- or DMSO-treated moDCs during live cell imaging to monitor calcium flux in real
time. Replicate means from 3 independent studies are shown. P values are shown for early (<60 s) and late (>60 s) T cell calcium flux after initial moDC:T cell
interaction by comparing the mean AUCs after stimulation with B-I09- or DMSO-treated moDCs, paired t-test.
B-I09-pretreated (20µM), LPS-stimulated moDCs. B-I09 or
vehicle was also added to the MLR medium once on day 0 to
maintain XBP-1s suppression during culture unless otherwise
indicated.
B-I09 was not toxic toward human T cells in treated
allogeneic co-cultures (Supplemental Figure 4A) and we
were unable to detect significant amounts of XBP-1s in DC-
allostimulated T cells (Supplemental Figure 4B). Although
CD3/CD28 bead-stimulation produced significant amounts
of XBP-1s in responder T cells (Supplemental Figure 4C),
B-I09 had no suppressive effect on these responder T cells
(Supplemental Figure 4D). Taken together, these findings
indicate that the immune suppressive effect of XBP-1s
inhibition acts primarily on human moDCs, impairing their
allostimulatory capacity, and secondarily limits allogeneic T
cells.
XBP-1s Blockade Impairs Human moDC
Migration and Induction of T Cell Calcium
Flux
TLR4 facilitates the migration of moDCs by inducing CCR7
surface expression (45). In trans-well assays, B-I09 abrogates
moDCs motility toward the CCR7 ligands, CCL19, and
CCL21, compared to vehicle-treated cells (Figures 1E,F). T cell
activation is a chief function of DCs. Despite intact potential
by the allogeneic moDCs to mediate costimulation by CD86
(Supplemental Figure 3A), we identified that T cell activation
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via early (<60 s) phase calcium flux was reduced in response to
B-I09-treated moDCs (Figure 1G).
XBP-1s Inhibited moDCs Reduce Th1
Differentiation
Since Th1 cells are implicated in GVHD pathogenesis (46),
we investigated the effect of B-I09 on Th1 and Th2 responses
in vitro. B-I09 reduced LPS-stimulated moDC production of
p40 cytokines, implicated in Th1 differentiation (Figure 2A),
without impairing moDC TNFα production (Figure 2B). T
cells stimulated by allogeneic moDCs pretreated with B-I09,
along with B-I09 added to the co-culture once on day 0 had
a significantly reduced Th1 response compared to controls
(Figures 2C,D,G). Conversely, XBP-1s blockade significantly
increased the amount of Th2 cells after 5 days of culture in
a proportional manner (Figures 2E-G). The shifts in Th1 were
consistent with reduced p40 cytokine production by moDCs
treated with B-I09.
Targeting XBP-1s Abrogates moDC
Production of IL-1β, TGFβ, and Diminishes
Alloresponder Th17 Differentiation
We next investigated whether B-I09 could reduce Th17-
inducing cytokines by LPS-stimulated moDCs. XBP-1s blockade
significantly suppressed IL-1β production by human moDCs
FIGURE 2 | XBP-1s inhibited moDCs reduce Th1 differentiation. (A,B) ELISAs were used to determine the concentration of IL-12/23 p40 cytokines or TNFα in the
supernatants of B-I09- or DMSO-treated moDCs after 24 h of LPS stimulation. Replicate means from 8 (IL-12/23 p40) and 2 (TNFα) independent experiments are
shown, Dunnett’s test. (C–G) T cells were cultured with B-I09 or DMSO pre-treated moDCs (moDC:T cell ratio of 1:30), and additional B-I09 (20µM) or DMSO (0.1%)
was added once on day 0. Harvested T cells were evaluated on day +5 for Th1 (CD4+, IFNγ+) and Th2 (CD4+, IL-4+) phenotype. Percentage or absolute numbers
of Th1 (C,D) and Th2 (E,F) are shown. (G) Representative contour plots show CD4+ Th1 vs. Th2 cells on day +5 of the allogeneic co-culture. Means of 8
independent experiments are shown, paired t-test.
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FIGURE 3 | Targeting XBP-1s abrogates human moDC production of IL-1β, TGFβ, and diminishes alloresponder Th17 differentiation. (A–C) Supernatant
concentrations of IL-1β, TGFβ, or IL-6 from LPS-stimulated moDCs exposed to B-I09 or DMSO after 24 h of culture are shown. Replicate means from 5 (IL-1 β), 3
(TGFβ), and 4 (IL-6) independent experiments are shown, paired t-test. (D–H) T cells were cultured with B-I09 or DMSO pre-treated moDCs (moDC:T cell ratio of
1:30), and additional B-I09 (20µM) or DMSO (0.1%) was added once on day 0. pSTAT3+ CD4+ T cells were analyzed at day +5 by flow cytometry (D) and
representative histograms are shown (E). Means from 3 independent experiments are shown, paired t-test. (F) Total STAT3 was measured in T cells from co-cultures
of DCs and T cells treated with B-I09 or DMSO. Means from 3 experiments are shown. In similarly treated co-cultures, the supernatant concentration of IL-17 was
quantified (G) and Th17 (CD4+, CCR6+, IL-17A+) differentiation was evaluated by flow cytometry (H,I). Replicate means from 3 (IL-17 ELISA) and 4 (Th17)
independent experiments, paired t-test. (I) Representative contour plots are shown.
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(Figure 3A) and eliminated TGFβ from the supernatant of LPS-
stimulatedmoDCs (Figure 3B). IL-1β is an essential co-factor for
IL-6 signal transduction (47). Despite ample IL-6 production by
B-I09- or DMSO-treated moDCs (Figure 3C), CD4+ T cells co-
cultured with these moDCs in the presence of B-I09 displayed
significantly less STAT3 phosphorylation (Figures 3D,E). Total
STAT3 expression within T cells stimulated by B-I09- or
DMSO-treated moDCs was similar (Figure 3F). Moreover, Th17
differentiation was significantly decreased by XBP-1s inhibition
(Figures 3G–I) and partially rescued by adding IL-1β, but not
TGFβ, to B-I09 treated co-cultures (Supplemental Figure 5).
moDC XBP-1s Directs iTreg Differentiation
via TGFβ
As XBP-1s-inhibited moDCs impaired Th17 differentiation,
we were surprised to observe that such moDCs also
significantly reduced responder Treg frequency in treated
alloMLRs (Figures 4A,B), though the suppressive function
of antigen-specific Tregs remained intact (Figure 4C).
We then investigated whether the reduction in Tregs
stimulated by B-I09-treated moDCs was due to impaired
differentiation of iTregs or suppression of nTregs. Treg-
depleted Tconv or purified nTregs were cultured with DMSO-
FIGURE 4 | moDC XBP-1s direct human iTreg differentiation via TGFβ. T cells were cultured with B-I09 or DMSO pre-treated moDCs (moDC:T cell ratio of 1:30), and
additional B-I09 (20µM) or DMSO (0.1%) was added once on day 0. (A) Percentage of Tregs (CD4+, CD127−, CD25+, Foxp3+) in the 5-day co-cultures, with
representative contour plots shown (B). Means from 6 independent experiments are shown. (C) The suppressive capacity of harvested moDC-allostimulated Tregs
was tested at different ratios of Treg to T cell responders stimulated by fresh allogeneic moDCs (moDC:responder T cell ratio 1:30) in alloMLRs. No additional B-I09 or
DMSO was added. Graph shows mean percent T effector (Teff) proliferation measured by Ki-67. Means from 3 independent experiments are shown. To generate
inducible Tregs, Treg-depleted CD4+ Tconv were stimulated by B-I09 or DMSO-pretreated allogeneic moDCs at a moDC:T cell ratio of 1:30. B-I09 or DMSO was
added once on day 0. Magnetic bead enriched natural Tregs (CD4+, CD25+) were similarly treated in allogeneic Treg:moDC co-cultures. Treg populations were
evaluated by flow cytometry on day +5. Means from 4 iTreg and 4 nTreg independent experiments are shown, paired t-test. Percentage and absolute number of iTreg
(D,E) and nTreg (F,G) are shown. (H) Representative contour plots are shown for iTreg and nTreg. (I) Representative contour plots show that adding recombinant
human TGFβ rescues iTreg generation in Treg-depleted alloMLRs treated with B-I09 vs. DMSO. 1 representative experiment of 2 independent studies is shown. (J) T
cell proliferation (MTS colormetric assay) at day +5 among Treg-depleted alloMLRs treated with B-I09 or DMSO, with recombinant human TGFβ added as indicated.
Replicate means from 4 independent experiments are shown, Dunnett’s test.
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or B-I09-pretreated, allogeneic moDCs, and DMSO or B-
I09 was also added to the media, respectively. XBP-1s
inhibition significantly reduced both the frequency and
absolute number of iTregs stimulated by allogeneic moDCs
(Figures 4D,E,H) in contrast to nTregs (Figures 4F,G,H).
Based on these data, we surveyed known moDC-mediated
mechanisms for iTreg generation. The expression of indolamine
2,3-deoxygenase (48) was similar among B-I09- or DMSO-
treated moDCs (Supplemental Figures 6A,B), as was
STAT5 phosphorylation among the DC-allostimulated T
cells (Supplemental Figures 6C,D). Instead, we discovered
that exogenous TGFβ rescued the differentiation of iTregs
in the co-cultures containing XBP-1s-inhibited moDCs
(Figure 4I). Moreover, adding TGFβ to Treg-depleted, MLRs
stimulated by B-I09-treated moDCs provided even greater
suppression of allogeneic T cells (Figure 4J). These data suggest
that XBP-1s-mediated TGFβ production by human moDCs
contributes to allogeneic iTreg differentiation, and that moDC
XBP-1s activity is not required for Treg suppressive potency or
nTreg responses.
XBP-1s Is Dispensable for Anti-tumor
Activity by CD8+ Cytotoxic T Lymphocytes
and NK Cells
While inhibiting moDC-XBP-1s in alloMLRs impaired the
proliferation of responder T cells, CTLs generated with B-I09-
treated stimulators exhibited intact tumor specific lytic function
(Figure 5A). Compared to unloaded moDCs, T cell responses
to clinically relevant pathogens using peptide-loaded, B-I09
exposed autologous moDCs permitted a measureable response to
CMV, EBV, influenza, and tetanus albeit significantly less robust
FIGURE 5 | XBP-1s is dispensable for anti-tumor activity by CD8+ cytotoxic T lymphocytes and NK cells. (A) Replicate mean specific lysis by human CD8+ CTL
generated in vitro using PBMCs stimulated by irradiated U937cells (1:1) on days 0 and +7 of a 10–12 day culture. B-I09 or DMSO was added once on days 0 and
+7. Tumor-specific killing by purified CD8+ T cells was determined using fresh U937 cells. U937 lysis was measured by a colorimetric assay after 4 h. Triplicate means
from 3 independent experiments are shown. (B) T cell proliferation stimulated by autologous moDCs loaded with CMV, EBV, influenza, or tetanus peptides is shown.
B-I09 or DMSO was added once on day 0. T cell proliferation (MTS colormetric assay) was measured on day +3. Replicate means from 4 independent experiments
are shown, Dunnett’s test. (C) Mean specific lysis by human NK cells against K562 targets is shown. B-I09 or DMSO was added at the outset of the culture. K562
lysis was measured by a colorimetric assay after 4 h. Replicate means from 3 independent experiments are shown. (D) NK cell proliferation stimulated by allogeneic
moDCs (moDC:NK cell ratio 1:10) or IL-2 plus IL-15. NK cell proliferation (MTS colormetric assay) was measured on day +5. Replicate means from 3 independent
experiments are shown.
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than DMSO-treatment of peptide-loaded DCs (Figure 5B). In
evaluating the effect of XBP-1s-inhibited moDCs on responder
T cell memory phenotypes after 5 days of stimulation,
we identified that blocking the moDC ER stress response
increased the proportion of non-alloreactive, naïve CD8+ T
cells vs. alloreactive central and effector memory CD8+ T cells
compared to vehicle controls (Supplemental Figures 7A,B). The
proportion of responder CD4+ T cell memory subsets was
similar regardless of B-I09- or DMSO-treatedmoDC-stimulation
(Supplemental Figures 7C,D).
NK cells and moDCs both constitutively express XBP-1s
(49). The functional significance of XBP-1s in NK cells is not
known. Because NK cells can mediate important anti-tumor
effects after allo-HCT, we investigated the effect of B-I09 on
NK cell lytic capacity and proliferative responses. Human NK
cells readily destroyed K562 targets in the presence of B-I09 or
DMSO (Figure 5C). Despite their exposure to B-I09 NK, cells
proliferated when stimulated by allogeneic, immature moDCs or
a cocktail of IL-2 and IL-15 (Figure 5D).
XBP-1s Blockade Reduces Human Skin
Graft Rejection and Xenogeneic GVHD, Yet
Preserves in vivo Generation of Anti-tumor
CTL
Skin is a highly immunogenic tissue and a critical target-
organ in GVHD (1). To test the efficacy of B-I09 in vivo
using human immune cells, NSG mice were transplanted with
a human skin xenograft using a well-established model (33, 36).
After 30 days to heal, mice were later injected with 5 × 106
human donor PBMCs allogeneic to the skin to induce graft
rejection and xenogeneic GVHD (33, 36). B-I09 or vehicle was
administered at 30mg/kg by intraperitoneal injection 5 days
a week for 3 weeks. XBP-1s blockade significantly reduced
skin graft rejection by the allogeneic PBMCs, as measured
on day +21 after the adoptive transfer of allogeneic PBMCs
(Figures 6A,B). Importantly, B-I09 also significantly reduced
xenogeneic GVHD by the human T cells against murine liver
(Figures 6A,C) and modestly against mouse lungs that did
not quite reach statistical significance (Figures 6A,D). In vivo
XBP-1s inhibition by B-I09 could be seen in CD3 negative
cells isolated from the recipient spleens (Figure 6E). Consistent
with in vitro observations, B-I09 significantly reduced the
amount of human Th17 cells (CD4+, IL-17A+) in the mouse
spleens (Figures 7A,B). Human Tregs (CD4+, CD127−, CD25+,
Foxp3+) recovered from the host spleens were similar among B-
I09- or vehicle-treated mice (Figures 7C,D). While B-I09-treated
mice demonstrated a significant decrease in Th1 cells (CD4+,
IFNγ+), Th2 cells (CD4+, IL-4+) were not increased as observed
in vitro (Figures 7E-G).
We used an established method to generate human anti-
tumor CTL in vivo and then test their specific killing (26,
33, 50). NSG mice received human PBMCs (30 × 106) and
were inoculated with irradiated U937 cells (10 × 106) on
days 0 and +7. Mice were treated with B-I09 or vehicle
as described above, and human CD8+ T cells were isolated
from the spleens of euthanized recipients during days +10-
12. CD8+ CTLs from B-I09-treated mice demonstrated tumor
killing equal to CTLs from vehicle-treated recipients, and
both were significantly more potent than CD8+ CTLs from
unvaccinated controls (Figure 7H). Preliminary data from a pilot
cohort of patients undergoing allogeneic HCT (5 with acute
GVHD and 5 without), suggests that the amount of intracellular
XBP-1s is significantly increased in CD1b+, epidermal DCs
among skin biopsies from patients with acute GVHD compared
to no GVHD controls (Supplemental Figures 8A–C). Though
not statistically significant, we also observed a trend toward
increased CD1b+, XBP-1s+epidermal DCs in the GVHD cohort
(Supplemental Figure 8B). This observation among a limited
number of patients is provocative and merits the prospective
study of XBP-1s+ DCs in acute GVHD pathogenesis.
DISCUSSION
We demonstrated that blocking XBP-1s in human moDCs
significantly reduced IL-1β and IL12/23p40 production during
their interaction with donor T cells, suppressing Th1 and
Th17 differentiation. While XBP-1s inhibition restrained T
cell alloreactivity, anti-tumor responses by CTLs and NK cells
remained intact. While rodent models have shown targeting
XBP-1s in B cells reduces chronic GVHD without impairing
graft- vs.-leukemia (GVL) effects (25), we now demonstrate that
suppressing XBP-1s in human DCs limits acute GVHD without
impairing donor immunity toward cancer. We also detected a
partial response toward clinically relevant infectious antigens by
T cells stimulated by XBP-1s-inhibited, peptide loaded moDCs.
We showed XBP-1s inhibition protected human skin grafts
from alloreactive T cell rejection in vivo. Xenogeneic GVHD
mediated by human T cells was also decreased by targeting XBP-
1s. Altogether, our data show that XBP-1s is a relevant therapeutic
target to suppress key aspects of DC function and prevent GVHD
after alloHCT.
Our results are consistent with prior studies which
demonstrate that eliminating ASC or the NLRP3 inflammasome
in bone marrow transplant recipients significantly reduces
GVHD in mice (15). Our approach substantially extends these
data by interrogating XBP-1s in human cells and demonstrating
regulation of NLRP3 activation in the context of ER stress (9, 51).
While targeting either the inflammasome or XBP-1s reduces
Th17 differentiation (15), XBP-1s inhibition differs from NLRP3
blockade by also significantly reducing Th1 and iTreg responses.
This defect in moDC supported human iTreg generation is
correctable by adding exogenous TGFβ, which is otherwise
absent from B-I09-treated moDCs. We show XBP-1s blockade
does not diminish the number or frequency of allo-stimulated
nTregs or total Treg suppressive potency. Interestingly, XBP-1s
inhibition was not detrimental to human Tregs in vivo. In
the xenogeneic transplant experiments, recipient mice were
transplanted with whole human PBMCs. Though alloMLRs are
restricted to T cells and moDCs, we speculate the more diverse
non-moDC constituents of the PBMC inoculum may potentially
rescue Tregs in vivo by providing TGFβ (52). Additionally,
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FIGURE 6 | XBP-1s blockade reduces human skin graft rejection and xenogeneic GVHD. NSG mice received a 1 cm2 split thickness human skin graft. After 30 days
of rest to permit engraftment, 5 × 106 human PBMCs (allogeneic to the skin) were injected into the mice. Unique pairs of donor skin and allogeneic PBMCs were
used for each set of experiments. B-I09 30 mg/kg or vehicle was given by i.p. injection 5 days a week for 3 weeks. Mice were humanely euthanized and the skin graft,
spleen, lung, and liver were harvested from the recipient on day +21 from time of PBMC injection. (A) Representative H&E sections compare skin graft rejection and
xenogeneic GVHD in the liver and lung among no PBMC controls, mice that received PBMCs plus vehicle, and mice that received PBMCs plus B-I09 (100X). (B–D)
Bar graphs show skin graft rejection and xenogeneic GVHD scores (blinded assessment) at day +21. (E) Representative contour plots show the amount of detectable
XBP-1s in CD3 negative cells residing in the murine spleen at day +21. Pooled data from two independent experiments, up to 7 mice per group, Mann–Whitney test.
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FIGURE 7 | XBP-1s inhibition reduces pathogenic Th17 and Th1 cells, yet preserves generation of anti-tumor CTL and Tregs in vivo. NSG mice were transplanted
with human skin grafts and allogeneic PBMCs and treated with vehicle or B-I09 exactly as described. On day +21, the mouse spleens were harvested and human T
cell phenotypes were determined by flow cytometry. The amount of human (A,B) Th17s (CD4+, IL-17A+), (C,D) Tregs (CD4+, CD127−, CD25+, Foxp3+), Th1s
(CD4+ IFNγ+), and Th2s (CD4+, IL-4+) (E–G) isolated from the recipient spleen at day +21 are shown. Pooled data from two independent experiments, up to 7 mice
per group, Mann-Whitney test. (H) Replicate mean specific lysis by human CD8+ CTL generated in vivo using NSG mice transplanted with human PBMCs (30 × 106)
and vaccinated with irradiated U937cells (10 × 106) on days 0 and +7. Mice received B-I09 or vehicle as described. For these experiments, recipients did not receive
human skin. U937 lysis was measured by a colorimetric assay after 4 h using purified human CD8+ T cells from recipient spleens at days +10–12. Replicate mean
tumor lysis values shown are from 1 of 2 independent experiments, Tukey’s test.
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the human and murine TGFβ1 genes share 66% nucleotide
homology and it is possible that cross-reactive murine TGFβ
could also rescue the human iTregs in vivo (53).
Targeting XBP-1s with B-I09 or siRNA supports translation
of our proposed strategy in GVHD prevention. While we show
that anti-tumor responses by CTLs and NK cells remain intact
in vitro, we acknowledge that these experiments do not fully
replicate the biology of GVL in vivo. Despite this limitation, our
study design demonstrates the relevance of DC XBP-1s in human
GVHD and that targeting XBP-1s does not impair donor anti-
tumor immunity.We surmise that the ability of the DC to express
critical T cell costimulatory molecules, such as CD86, despite
XBP-1s inhibition is important for the preserved GVL effect. The
essential role for CD86 in CD8 CTL-mediated tumor clearance is
well-demonstrated (54–56). Furthermore, the blunting of GVHD
is likely driven by impaired DC production of IL-1β and reduced
differentiation of pathogenic Th1 and Th17 cells by XBP-1s
blockade.
Silencing XBP-1 in intratumoral suppressive DCs enhances
T cell responses to cancer antigens, a result that is distinct
from our observations in GVHD (57). It is reasonable that ER
stress mediators support antigen-presentation by DCs during
acute GVHD. In contrast, sustained, unremitting ER stress in
tumor bed DCs, along with associated metabolic alterations (57),
abrogates their immunostimulatory activity. For example, in
ovarian cancer, ER stress leads to lipid peroxidation, impaired
antigen presentation, and blunted stimulatory capacity toward
responder T cells (57). Alternatively, context-dependent ER stress
effects could depend on tumor or GVHD target-organ location,
and/or be influenced by a different cytokine milieu altogether.
Understanding the context-dependent effects of ER stress in
cancer vs. inflammation is an area of active interest.
The ER stress response of DCs represents a novel biologic
target to prevent GVHD in humans. In summary, targeting
DC XBP-1s is an innovative approach to selectively impair
alloreactive T cells and pathogenic Th1/Th17 differentiation,
while maintaining donor immune mediated anti-leukemia
responses, that deserves consideration for clinical trials of acute
GVHD prophylaxis. Additionally, a prospective investigation
of epidermal XBP-1s+, CD1b+ DCs and their potential
involvement in the pathogenesis of acute GVHD warrants future
study.
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